Table 1

Cumulative incidence and mean scores of arthritis in mice treated with wild-type or IFN-γR KO DBA/1 MSCs or with C57BL/6 MSCsa

Experiment

Routeb

Administration timec

Treatmentd

Cumulative incidencee, fraction (percentage)

Score of arthritis, mean ± SEMe, f


1

i.v.

Day -1

Control

4/8 (50%)

2.0 ± 0.9

Wild-type MSCs

1/2 (50%)

1.5 ± 1.5

IFN-γR KO MSCs

3/7 (43%)

1.6 ± 1.0

Treg cells

2/8 (25%)

0.4 ± 0.3

2

i.v.

Day 16

Control

4/10 (40%)

1.3 ± 0.7

Wild-type MSCs

6/8 (75%)

2.1 ± 0.6

IFN-γR KO MSCs

4/10 (40%)

0.8 ± 0.4

3

i.v.

Days 16 and 23

Control

5/10 (50%)

3.0 ± 1.4

Wild-type MSCs

5/9 (56%)

2.5 ± 0.9

IFN-γR KO MSCs

5/10 (50%)

2.0 ± 0.8

4

i.p.

Days 16, 23, and 30

Control

7/8 (88%)

5.1 ± 1.5

Wild-type MSCs

6/7 (86%)

5.3 ± 1.2

IFN-γR KO MSCs

8/9 (89%)

4.6 ± 1.6

5

i.p.

Days 16, 23, and 30

Control

7/11 (64%)

1.3 ± 0.5

C57BL/6 MSCs

8/11 (73%)

2.7 ± 1.2


aMice were immunized with collagen type II in complete Freund's adjuvant on day 0 and were treatedb either intravenously (i.v.) or intraperitoneally (i.p.) on the indicated time pointsc with wild-type mesenchymal stem cells (MSCs), interferon-gamma receptor knockout (IFN-γR KO) MSCs, C57BL/6 MSCs, regulatory T (Treg) cells, or phosphate-buffered saline (control group)d. eArthritic incidence and score of arthritis in all groups at day 35. fArthritic scores were not significantly different between control treatment and treatment with wild-type or IFN-γR KO DBA/1 MSCs or C57BL/6 MSCs or with Treg cells. SEM, standard error of the mean.

Schurgers et al. Arthritis Research & Therapy 2010 12:R31   doi:10.1186/ar2939

Open Data